Pennsylvania Law now allows medical providers to prescribe marijuana as a pain treatment. As we learned during a hearing on the United States' request to modify the terms of a citizen's supervised release after he served a long prison term, Pennsylvania's permission may confuse some Pennsylvanians as to their ability to use marijuana of any type for any reason under federal law. At the formerly incarcerated citizen's request, we held a hearing to address his confusion. We strongly reminded
But given the citizen's confusion and the absence of a clear statement from a Pennsylvania federal court in the criminal context of federal law's absolute prohibition after the Commonwealth's allowance of medical marijuana, we defer modifying the terms of his supervised release for thirty days so he can prove no further use of a controlled substance and obtain a prescribed pain treatment protocol not involving controlled substances, including marijuana. He assured us of no further confusion and he, and others, are now on notice.
I. Background
Dawud Bey plead guilty in February 2005 to conspiracy to manufacture and distribute cocaine under
In April 2018, over three years into his five-year term of supervised release, Mr. Bey reported to the U.S. Probation Office smelling of marijuana.
Mr. Bey swore he uses medical marijuana as pain management to relieve chronic pain suffered over the past few years.
The United States sought to modify-not revoke-Mr. Bey's terms of supervised release to require he "submit to home detention for a period of 30 days, and comply with the [l]ocation [m]onitoring requirements as directed by the U.S. Probation Office."
II. Analysis
A. Mr. Bey admits possessing and using marijuana.
Despite a wave of marijuana legalization at the state level, the Supreme Court has held federal law's treatment of marijuana is clear: "marijuana [i]s contraband for any purpose; in fact, by characterizing marijuana as a Schedule I drug, Congress expressly found that the drug has no acceptable medical uses."
Marijuana is one of many drugs in the United States classified and governed by the Controlled Substances Act, "a closed regulatory system making it unlawful to manufacture, distribute, dispense, or possess any controlled substance except in a manner authorized by the [Act]."
The Controlled Substances Act contains no exception-express or implied-for medically-prescribed marijuana, a mandate the Supreme Court made clear in United States v. Oakland Cannabis Buyers' Cooperative .
The Supreme Court reversed. The Court held implying "a medical necessity exception for marijuana is at odds with the terms of the Controlled Substances Act," which "reflects a determination that marijuana has no medical benefits worthy of an exception (outside the confines of a Government approved research project)."
The Supreme Court again emphasized marijuana's contraband status under the Controlled Substances Act in Gonzales v. Raich .
The Supreme Court's interpretation of the Controlled Substances Act compels we conclude Mr. Bey may not use medical marijuana under federal law. A Pennsylvania statute or policy to the contrary cannot override a conflicting federal statute, as "[t]he Supremacy Clause unambiguously provides that if there is any conflict between federal and state law, federal law shall prevail."
We therefore join what Judge G. Michael Harvey has described as "the chorus" of federal courts around the country concluding a federal supervisee's state-authorized possession and use of medical marijuana violates the terms of federal supervised release.
B. We decline to immediately modify Mr. Bey's supervised release.
We nonetheless decline to immediately modify Mr. Bey's supervised release. We will allow Mr. Bey thirty days to show he has not used marijuana through testing and fourteen days to obtain a doctor-prescribed prescription protocol to address Mr. Bey's pain management.
Our Court of Appeals has "repeatedly expressed concern that conditions of supervised release be sufficiently clear to enable individuals on supervised release to freely choose between compliance and violation."
Mr. Bey could have reasonably and in good faith read the terms of his supervised release-which prohibits him from using any controlled substance "except as prescribed by a physician "
Under similar circumstances Judge Lamberth in United States v. Parker
While we take seriously our obligation to ensure supervisees comply with the terms of supervised release, we must be equally mindful "the primary purpose of supervised release is to facilitate the integration of offenders back into the community rather than to punish them."
III. Conclusion
In an accompanying Order, we granted the United States' motion to modify the terms of Mr. Bey's supervised release for a period of thirty days of home confinement.
Notes
ECF Doc. No. 808, at 1; see also ECF Doc. No. 445.
See ECF Doc. No. 808, at 2-3.
ECF Doc. No. 1180, at 1.
Gonzales v. Raich ,
United States v. Johnson ,
United States v. Schostag ,
See United States v. Harvey ,
United States v. Johnson ,
United States v. Bagdy ,
ECF Doc. No. 808 at 3 (emphasis added).
ECF Doc. No. 1180 at 2.
Pennsylvania federal courts addressing the interplay between Pennsylvania-sanctioned medical marijuana use and the Controlled Substances Act have not done so in the context of federal supervised release. See, e.g. , PharmaCann Penn, LLC v. BV Dev. Superstition RR, LLC ,
Parker ,
Bagdy ,
United States v. Murray ,
Schostag ,
Parker ,
ECF Doc. No. 1185.
Mr. Bey does not argue, and nothing in our opinion today concerning a deferred modification of Mr. Bey's supervised release, addresses the affect of existing legislation restricting the United States Department of Justice from using certain funds to pursue individual prosecutions of possessing and using medical marijuana under the Controlled Substances Act. See Consolidated Appropriations Act, 2017, Pub. L. No. 115-31, § 537,
